Improvement ( n = 42) | Non-improvement ( n = 36) | p value | |
---|---|---|---|
Sex (male/female) | 24/18 | 26/10 | 0.237 |
Age (years) | 69 (13) | 71 (34) | 0.996 |
APACHE II score | 24 (12) | 24 (12) | 0.980 |
SOFA score | 11 (4) | 11 (7) | 0.996 |
MAP at baseline (mmHg) | 62 (10) | 72 (22) | 0.343 |
Creatinine at baseline (mg/dl) | 1.28 (1.72) | 1.65 (1.85) | 1.000 |
Lactate level at baseline (mmol/L) | 3.2 (5.9) | 4.2 (4.9) | 0.599 |
Patients with diabetes mellitus | 13 | 11 | 1.000 |
Patients received corticosteroid therapy | 8 | 5 | 0.762 |
The times of PMX therapy | 1 (1) | 1 (1) | 0.281 |
Total PMX treatment time (min) | 1598 (2972) | 1412 (2254) | 0.237 |
Inotropic score at pre-PMX | 24.7 (21.0) | 10.3 (18.6) | 0.001 |
Inotropic score at post-PMX | 6.8 (15.6) | 16.6 (32.8) | 0.037 |
Vasopressor dependency index at pre-PMX (/mmHg) | 0.33 (0.44) | 0.19 (0.29) | 0.019 |
Vasopressor dependency index at post-PMX(/mmHg) | 0.13 (0.26) | 0.14 (0.28) | 0.845 |
PaO2/FIO2 ratio at pre-PMX | 210 (234) | 199 (206) | 0.980 |
PaO2/FIO2 ratio at post-PMX | 254 (181) | 172 (156) | 0.041 |
Endotoxin level before the PMX treatment (pg/mL) | 15.8 (60.5) | 6.1 (23.7) | 0.195 |
Endotoxin level after the PMX treatment (pg/mL) | 1.4 (18.2) | 0.8 (0.7) | 0.267 |
Suspected causative microorganisms (GNR/GPC/GPR/unknown origin) | 24/6/2/10 | 17/6/0/13 | 0.428 |
Median survival time (days) | 72 | 131 | 0.172 |
Ventilator-dependent time (days) | 13 (33) | 7 (42) | 0.557 |